Psychedelics Investing: An Overview for Investors

Psychedelics investing is becoming the latest trend in the alternative venture markets with the dawn of a new appreciation for the medical benefits of plant-based medicines.

The possibility of investing in the development of psychedelic medicine is now possible thanks to the launch of publicly traded psychedelic stocks across Canadian exchanges.

The shroom boom investment opportunity is being welcomed, and companies are already listing on the Canadian Securities Exchange, the NEO Exchange and even the TSX Venture Exchange.

But the potential doesn’t stop just there — while there is already a decent crop of psychedelic stocks, more and more companies focused on psychedelic therapy and psychedelic research are set to arrive.

Like its alternative drug sibling cannabis, the psychedelics space is starting with the promise of novel psychedelic medicine and psychedelic drugs to support its operation.

Various medical-grade studies have been launched, including some from psychedelic stocks that are already trading. They are evaluating the potential of psychedelic substances, such as psilocybin and MDMA, in treating serious mental health conditions.

Psychedelic researchers focused on psychedelic medicine and psychedelic drugs have shown that these substances have promise for treating ailments including anxiety, addiction, depression, substance dependency, attention deficit hyperactivity disorder and even post-traumatic stress disorder (PTSD).

In fact, some of the most advanced modern studies are evaluating the efficacy of psychedelic compounds as a treatment for PTSD in patients.

Notably, these psychedelic studies have secured support from the biggest medical authority in the US, bringing them closer and closer to the pharmaceutical industry.

The US Food and Drug Administration (FDA) has shown a willingness to engage with work in the psychedelics space, as per market participants focused on psychedelic treatment. And the option for these treatments to become legal through FDA approval is beginning to seem more like an inevitability.

Thanks to the FDA’s willingness to participate and encourage psychedelic research, the business world has taken an increased interest in these medicines and the companies behind them.

Business arbiters have also started to take a closer look at the space and are sharing encouraging words about the progress and outlook that psychedelics has for investors.

A report put forth by an independent research group and sponsored by the NEO Exchange shows that in the first half of 2020, US$150 million was raised by psychedelics-focused companies. The research group projects that the global psychedelics industry may reach a total value of US$7 billion by the year 2027.

For now, investors are lining up and starting to ask how psychedelics investing is moving ahead, and where exactly the investment opportunity will be within this quickly growing sector. Read through the articles here to get your start on psychedelics investments and to learn more about the industry directly from the people shaping it.

Don’t forget to follow @INN_LifeScience for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.